Published online Oct 21, 2017. doi: 10.3748/wjg.v23.i39.7160
Peer-review started: June 30, 2017
First decision: July 27, 2017
Revised: September 21, 2017
Accepted: September 29, 2017
Article in press: September 28, 2017
Published online: October 21, 2017
Processing time: 114 Days and 22.6 Hours
To identify the potential risk factors of cholangiocarcinoma, we determined the characteristics of cholangiocarcinoma patients among 5 different regions of Thailand.
All patients diagnosed with cholangiocarcinoma between 2008 and 2013 were identified using the Nationwide Hospital Admission Data registry (n = 39421). Baseline characteristics, comorbidities and survival were abstracted.
The annual incidence during the study period was stable in all regions. Most patients lived in the Northeast (62.8%), followed by the North (16.9%), Central (12.3%), Bangkok (5.4%), and South (n = 2.6%) regions (P < 0.0001). Significantly more cholangiocarcinoma patients had diabetes, cirrhosis, and chronic viral hepatitis B/C infection than non-cholangiocarcinoma participants (diabetes: 11.42% vs 5.28%; cirrhosis: 4.81% vs 0.92%; hepatitis B: 0.74% vs 0.12%; and hepatitis C: 0.50% vs 0.10%, P < 0.0001 for all, respectively). The overall 1-year mortality rate was 81.7%, with a stable trend over time.
Diabetes and chronic liver diseases may be associated with cholangiocarcinoma in the Thai population.
Core tip: Cholangiocarcinoma is highly prevalent in Thailand, particularly in the Northeast region. The high cholangiocarcinoma incidence in this region is known to be associated with a high prevalence of liver fluke infection. Cirrhosis, diabetes, and chronic viral hepatitis B and C infections have been recently identified as risk factors for cholangiocarcinoma in Western countries. In this study, we found that diabetes and chronic liver diseases may be associated with cholangiocarcinoma in the Thai population. Further study to determine the magnitude of the impact of these factors on cholangiocarcinoma development in the Thai population is necessary.